You’ve in all probability seen compounding making headlines not too long ago, and never for the fitting causes. From so-called “customized” GLP-1s flooding the market to telehealth startups touting hormone “rebalancing” kits, compounding has develop into a buzzword for firms seeking to shortcut regulation. A lot of the scrutiny is justified; some firms exploit compounding to bypass proof requirements or chase quick income.
However when compounding is grounded in rigorous information, fills an actual market hole, and meets a medical want, it will possibly meaningfully speed up entry to therapies that might in any other case take years to succeed in sufferers. In girls’s well being, particularly, it will possibly bridge the hole between pressing unmet wants and sluggish regulatory timelines in a market ignored for much too lengthy.
WHAT IS COMPOUNDING?
When a doctor prescribes a compounded treatment, a licensed pharmacist prepares it by adjusting an FDA-approved drug to create a tailor-made formulation when no business choice meets the affected person’s wants. Merely put, compounding exists to fill gaps in care.
This performs a important position, for instance, with oncology sufferers who require customized dosages not supplied in business merchandise, or those that want medicines reformulated with out allergens. In restricted circumstances, compounding can even permit firms to ship new formulations to underserved populations utilizing confirmed pharmaceutical substances whereas persevering with towards FDA approval.
Accountable compounding is all the time:
- Anchored in proof
- Solely used when no FDA-approved choice exists, and sufferers would in any other case don’t have any entry
- And a part of an outlined regulatory plan
When aligned with these requirements, compounding can deliver scientific developments into actual‑world use years sooner—with out compromising rigor—particularly in areas the place funding and approvals lag.
WOMEN’S HEALTH AS A CASE STUDY
Girls’s well being is a long time behind different therapeutic classes in the case of FDA-approved choices. A current WEF-BCG report discovered that girls’s well being receives solely 6% of personal healthcare capital,and firms centered solely on girls’s well being seize lower than 1%. In the meantime, drug improvement averages 10–12 years and might exceed $2 billion per accepted product. Prices and timelines could be additional compounded by gender bias in medical analysis, regulatory requirements primarily based on male physiology, or inconsistent definitions of ladies‑particular circumstances. The result’s a good wider hole between what science can ship and what girls can really entry.
Compounding affords one strategy to shut that hole responsibly. When my firm, Daré, evaluated sildenafil—the identical lively ingredient in Viagra—for feminine arousal dysfunction, a long time of information and managed research supported its potential. But, 30 years after Viagra’s approval for males, nobody had put within the onerous work to do the analysis, develop the fitting formulation, and definitively reveal sildenafil’s impact on girls.
After in depth FDA engagement and rigorous improvement, we made our proprietary formulation for DARE to PLAY, the primary topical sildenafil cream for ladies, supported by revealed, peer-reviewed medical information, accessible by way of compounding. We did so as a result of the proof we generated was compelling, the necessity was pressing, and hundreds of thousands of ladies had been dwelling with out choices.
WHY SHOULD YOU CARE?
Compounding allowed us to present girls entry to a formulation that has been rigorously studied and clinically examined, the place no FDA-approved choice exists. We’re dedicated to FDA approval of the primary therapy for arousal dysfunction in girls, however we received’t let girls wait unnecessarily for an answer that we’ve demonstrated the science already helps.
RAISE THE BAR, WIDEN THE PATH
Compounding shouldn’t be a shortcut, nor a substitute for FDA approval. It may be a catalyst for innovation when used precisely as designed, to get credible, science-backed options to individuals who want them and mustn’t have to attend.
It permits innovators to widen entry in a managed, science-first means whereas persevering with the work towards FDA approval. For founders working in traditionally underfunded areas like girls’s well being, together with sexual well being, menopause, fertility, and pelvic ache, compounding affords a mannequin the place affected person want, scientific rigor, and market-building transfer in the identical course.
The way forward for accountable innovation isn’t about selecting between pace and rigor. We are able to and may ship each.
Sabrina Martucci Johnson is founder and CEO of Daré Bioscience.
